In recent years, as the capital city of Guizhou province, Guiyang has relished in its advantages, such as location, talent, information, and being the lead role of big data, and it is focused more than ever on development and ecology. It has accelerated efforts to develop the pharmaceutical industry in a market-oriented, integrated high-tech and centralized way. It also has vigorously developed the pharmaceutical and healthcare industry with the goal of big health (developing health care industry with big data and high-end technologies).
Guiyang aims to build a big health medicine industrial system covering various fields including medicine, pension, fitness and management.
The world's leading consulting firm, Boston Consulting Group, released its latest report, New Rules to Win in China's Pharmaceutical Market, in Beijing on Jan 23, 2015. The report pointed out that due to the aging population the average annual growth rate of China's pharmaceutical market is expected to reach 13-15 percent from 2011 to 2020.
Building the big health medicine industry as a mutual promotion of the big data industry is a positive move by Guiyang to ride the coattails of China's rapid growth in the pharmaceutical market.
With multiple advantages in ecological environment, climate, biological resources, ethnic medicine and drug varieties, Guiyang promotes industrial restructuring and upgrading so as to seize the commanding height of the new pharmaceutical industry.
As one of the four major producing areas of traditional Chinese medicine across the country, Guizhou enjoys unique climate conditions and a natural environment that is extremely rich in traditional Chinese medicine resources. It is known as the "treasure-house of natural medicines".
With the fore mentioned resources advantage and an industrial base, the pharmaceutical industry of Guiyang is already one of several advantaged industries in Guizhou. Guiyang has a total of 1,993 kinds of Chinese herbal medicine resources, accounting for 42 percent of the total number in the province, and owns 1,079 drugs brands (including 671 patented products), accounting for 48 percent of the total number in the province.
In 2014, Guizhou province issued the Plan of Guizhou Province New Medicinal Industry Development (2014-2017), which proposed to develop and expand the pharmaceutical industrial parks of Yibai, Wudang, Xiuwen, Qingzhen, Longli and Gui'an, with Guiyang as the core, and build an industrial circle for Guiyang's new pharmaceutical industry. Guizhou strives to make its new pharmaceutical industry output exceed 80 billion yuan ($12.1 million) by the end of 2017.
Guiyang has a sound industrial foundation ideal for developing a big health medicine industry. On Oct 30, 2014, some 66 new pharmaceutical industry projects across the province were started, including 36 projects in Guiyang, with a total investment of 14.63 billion yuan.
The construction of professional parks, including Wudang Pharmaceutical and Food (Health) Industrial Park, Xiuwen Zazuo Pharmaceutical Park, and Yibai Pharmaceutical Industrial Park,continue to be promoted, and industrial clusters represented by leading companies, such as Yibai, Jingfeng, Tongjitang, Jianxing, and Taibang, have been gradually formed.
